.After raising $170 thousand back in February, metabolic disease-focused BioAge Labs has filed to debut on the general public market.The Eli Lilly-partnered biotech expect to list on the Nasdaq under the icon "BIOA," according to documentations filed along with the Securities and also Swap Percentage. The firm has certainly not openly discussed an expected financial volume for the offering.The clinical-stage company proclaims lead applicant azelaprag, an orally provided small molecule slated to enter into stage 2 testing in combination with semaglutide-- marketed through Novo Nordisk under brand name Wegovy for weight-loss-- in the very first half of upcoming year. Semaglutide is also sold as Ozempic and also Rybelsus by Novo for diabetes.
Apelin receptor agonist azelaprag is developed to combine effectively with GLP-1 medications, improving fat burning while preserving muscle mass. The investigational medication was actually discovered to become well-tolerated one of 265 individuals throughout eight stage 1 tests, depending on to BioAge.Recently, BioAge gathered the help of Lilly to manage a test integrating azelaprag along with the Major Pharma's GLP-1/ GIP receptor agonist tirzepatide, which is actually industried for diabetic issues as Mounjaro and Zepbound for fat loss. The partners are currently administering a stage 2 test of azelaprag and also tirzepatide, with topline outcomes anticipated in the third quarter of 2025.The biotech is actually also organizing an insulin level of sensitivity proof-of-concept test assessing azelaprag as a monotherapy in the first one-half of next year to assist possible indicator expansion. On top of that, the business intends to ask the FDA for consent in the 2nd fifty percent of 2025 to introduce human testing for an NLRP3 prevention targeting metabolic diseases and neuroinflammation.BioAge's expected relocate to the public market observes a minor uptick in prepared biotech IPOs from Bicara Therapeutics and Zenas Biopharma. Zooming out, the latest IPO yard is actually a "blended picture," along with high-grade providers still debuting on the public markets, just in reduced numbers, according to PitchBook.